Home Healthcare Medical Equipment Cephalosporin Market by Generation (First-generation, Second-generation, Third-generation, Fourth-generation, and Fifth-generation), Type (Branded and Generics), Route of Drug Administration (Injection and Oral), and Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, and Sexually Transmitted Infection): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

Cephalosporin Market by Generation (First-generation, Second-generation, Third-generation, Fourth-generation, and Fifth-generation), Type (Branded and Generics), Route of Drug Administration (Injection and Oral), and Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, and Sexually Transmitted Infection): Global Opportunity Analysis and Industry Forecast, 2018 - 2025

Publisher: Allied Market Research
Publication Date: March, 2019
Healthcare / Medical Equipment
Pages: 239
Delivery Format: PDF

Report Features
Table of Contents
Pricing
Methodology
Request Sample
Compare Offers
Make an Offer

Cephalosporin is a group of semisynthetic, broad-spectrum antibiotics that is majorly used to treat bacterial infections. It resembles penicillin and hence, is used as an alternative for patients who are allergic to penicillin. It is used in the treatment of a variety of clinical conditions, including pneumonia, skin infections, strep throat, staph infections, tonsillitis, bronchitis, otitis media, and gonorrhea.
The major factors that contribute to the growth of the cephalosporin market include increase in R&D activities to develop highly efficient & safe drugs, upsurge in use of combination therapies, and rise in prevalence of pneumonia, tonsillitis, bronchitis, and gonorrhea. Moreover, increased approvals of drugs and growth in awareness about various infections & antibiotic resistance propel the market growth. However, side effects associated with cephalosporin and development of drug-resistant bacterial strains impede the market growth. Conversely, increase in mergers and acquisition among key vendors and development of combination therapies in the untapped market are anticipated to provide potential opportunities for the market growth.
The global cephalosporin market is segmented on the basis of generation, type, route of drug administration, application, and region. Based on generation, the market is divided into first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin. By type, it is bifurcated into branded and generics. Depending on route of drug administration, it is classified into injection and oral. The applications covered in the study include respiratory tract infection, skin infection, ear infection, urinary tract infection, sexually transmitted infection, and others. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
 The report provides an in-depth analysis of market trends, macro-economic indicators, and governing factors.
 This report provides an extensive analysis of the current and emerging market trends and dynamics in the market through 2017–2025 that helps identify the upcoming market opportunities.
 Recent industry trends and developments and the future opportunities are also covered.
 Extensive knowledge about the key market players and their strategies is provided.
 Comprehensive analysis of the various factors that drive and restrain the growth of the market is provided.

Key Market Segments
• By Generation
o First-generation Cephalosporin
o Second-generation Cephalosporin
o Third-generation Cephalosporin
o Fourth-generation Cephalosporin
o Fifth-generation Cephalosporin
• By Type
o Branded
o Generics
• By Route of Drug Administration
o Injection
o Oral
• By Application
o Respiratory Tract Infection
o Skin Infection
o Ear Infection
o Urinary Tract Infection
o Sexually Transmitted Infection
o Others
• By Region
o North America
 U.S.
 Canada
 Mexico
o Europe
 France
 Germany
 UK
 Italy
 Spain
 Rest of Europe
o Asia-Pacific
 Japan
 China
 India
 Australia
 Rest of Asia-Pacific
o LAMEA
 Brazil
 Saudi Arabia
 South Africa
 Rest of LAMEA
Key market players
The key players operating in this market include
• Allergan Plc
• Bristol-Myers Squibb Company
• Lupin Limited
• Sanofi
• Novartis International AG
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• Merck & Co., Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.

Select Plan

1 User License $5,370

5 Users License $6,450

Are you looking for a Consultant?

Email Us

Get a Quote

Offer Amount (Per user license)	Retail price (Per user license)
$ .00	$5,370

Are you looking for a Consultant?

Customers Who Viewed This Item Also Viewed